Evaluation of the Polyclonal ELISA HPV Serology Assay as a Biomarker for Human Papillomavirus Exposure

被引:19
作者
Coseo, Sarah E. [1 ]
Porras, Carolina [2 ]
Dodd, Lori E. [3 ]
Hildesheim, Allan [1 ]
Cecilia Rodriguez, Ana [2 ]
Schiffman, Mark [1 ]
Herrero, Rolando [2 ]
Wacholder, Sholom [1 ]
Gonzalez, Paula [2 ]
Sherman, Mark E. [1 ]
Jimenez, Silvia [2 ]
Solomon, Diane [4 ]
Bougelet, Catherine [5 ]
van Doorn, Leen-Jan [6 ]
Quint, Wim [6 ]
Safaeian, Mahboobeh [1 ]
机构
[1] NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA
[2] Fdn INCIENSA, Proyecto Epidemiol Guanacaste, Liberia, Costa Rica
[3] NIAID, Biostat Res Branch, Bethesda, MD 20892 USA
[4] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
[5] GlaxoSmithKline Biol, Rixensart, Belgium
[6] DDL Diagnost Lab, Voorburg, Netherlands
关键词
GRADE CERVICAL LESIONS; YOUNG-WOMEN; CHLAMYDIA-TRACHOMATIS; INFECTION; CANCER; RISK; DNA; VACCINE; GUANACASTE;
D O I
10.1097/OLQ.0b013e31822545c0
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Seropositivity to human papillomavirus (HPV)16 and 18 antibodies is used as a measure of cumulative HPV exposure and as a stratifier of HPV exposure for vaccine efficacy analyses. Overall performance of these assays, as a measure of HPV exposure, has not been evaluated. Methods: Using data from the enrollment phase of the HPV16/18 vaccine trial in Costa Rica, we evaluated the performance of the polyclonal enzyme-linked immunosorbent assay (ELISA) HPV16 and 18 serological assays as a measure of HPV exposure. Biologic (e. g., HPV infection at the cervix) and behavioral characteristics (e. g., lifetime number of sexual partners) with known associations with current and past HPV infection were used to define cases and controls (HPV exposed vs. not exposed). Prevaccination serum was measured for antibodies against HPV16 and 18 by ELISA; cervical samples were tested for HPV DNA using PCR SPF10/LiPA25. ELISA results were analyzed using receiver-operator characteristic curves; performance was evaluated at the manufacturer set cut point (HPV16 = 8, HPV18 = 7) and at cut points chosen to optimize sensitivity and specificity (HPV16 = 34, HPV18 = 60). Results: Defining cases as type-specific HPV DNA positive with high-grade abnormal cytology (i.e., combined molecular and microscopic markers of infection), HPV16-ELISA gave sensitivity that was lower at the optimal cut point than the manufacturer cut point (62.2 compared with 75.7, respectively; P = 0.44). However, specificity was higher (85.3 compared with 70.4, respectively; P < 0.0001). Similarly, HPV18-ELISA gave sensitivity that was lower at the optimal cut point than the manufacturer cut point (34.5 compared with 51.7, respectively; P = 0.40), with higher specificities (94.9 compared with 72.6, respectively; P < 0.0001). Conclusions: Modifying cut points did not improve the low sensitivity. The low sensitivity of this assay does not support its use for risk stratification or clinical settings.
引用
收藏
页码:976 / 982
页数:7
相关论文
共 23 条
[1]  
[Anonymous], 2006, SAS Users Group Int. (SUGI)
[2]   Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma [J].
Anttila, T ;
Saikku, P ;
Koskela, P ;
Bloigu, A ;
Dillner, J ;
Ikäheimo, I ;
Jellum, E ;
Lehtinen, M ;
Lenner, P ;
Hakulinen, T ;
Närvänen, A ;
Pukkala, E ;
Thoresen, S ;
Youngman, L ;
Paavonen, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (01) :47-51
[3]   Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas [J].
Baay, MFD ;
Quint, WGV ;
Koudstaal, J ;
Hollema, H ;
Duk, JM ;
Burger, MPM ;
Stolz, E ;
Herbrink, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (03) :745-747
[4]   Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of Infection [J].
Cecilia Rodriguez, Ana ;
Schiffman, Mark ;
Herrero, Rolando ;
Hildesheim, Allan ;
Bratti, Concepcion ;
Sherman, Mark E. ;
Solomon, Diane ;
Guillen, Diego ;
Alfaro, Mario ;
Morales, Jorge ;
Hutchinson, Martha ;
Katki, Hormuzd ;
Cheung, Li ;
Wacholder, Sholom ;
Burk, Robert D. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (05) :315-324
[5]   Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis [J].
Clifford, GM ;
Smith, JS ;
Aguado, T ;
Franceschi, S .
BRITISH JOURNAL OF CANCER, 2003, 89 (01) :101-105
[6]   Carcinogenicity of human papillomaviruses [J].
Cogliano, V ;
Baan, R ;
Straif, K ;
Grosse, Y ;
Secretan, B ;
El Ghissassi, F .
LANCET ONCOLOGY, 2005, 6 (04) :204-204
[7]   Seroprevalence and Correlates of Human Papillomavirus 16/18 Seropositivity Among Young Women in Costa Rica [J].
Coseo, Sarah ;
Porras, Carolina ;
Hildesheim, Allan ;
Cecilia Rodriguez, Ana ;
Schiffman, Mark ;
Herrero, Rolando ;
Wacholder, Sholom ;
Gonzalez, Paula ;
Wang, Sophia S. ;
Sherman, Mark E. ;
Jimenez, Silvia ;
Solomon, Diane ;
Bougelet, Catherine ;
van Doorn, Leen-Jan ;
Quint, Wim ;
Safaeian, Mahboobeh .
SEXUALLY TRANSMITTED DISEASES, 2010, 37 (11) :706-714
[8]   Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine [J].
Dessy, Francis J. ;
Giannini, Sandra L. ;
Bougelet, Catherine A. ;
Kemp, Troy J. ;
David, Marie-Pierre M. ;
Poncelet, Sylviane M. ;
Pinto, Ligia A. ;
Wettendroff, Martine A. .
HUMAN VACCINES, 2008, 4 (06) :425-434
[9]   Prevalence of HPV infection among females in the United States [J].
Dunne, Eileen F. ;
Unger, Elizabeth R. ;
Sternberg, Maya ;
McQuillan, Geraldine ;
Swan, David C. ;
Patel, Sonya S. ;
Markowitz, Lauri E. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (08) :813-819
[10]   THE MEANING AND USE OF THE AREA UNDER A RECEIVER OPERATING CHARACTERISTIC (ROC) CURVE [J].
HANLEY, JA ;
MCNEIL, BJ .
RADIOLOGY, 1982, 143 (01) :29-36